TUSC1抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: PC3 cell and human colon cancer tissue, Primary antibody: P12346(TUSC1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12346(TUSC1 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

The tumor suppressor candidate 1 (TUSC1) gene, located on human chromosome 9q34. has been implicated as a potential tumor suppressor in various cancers. TUSC1 is thought to regulate cell proliferation, apoptosis, and metastasis by interacting with signaling pathways such as EGFR and PI3K/Akt. Its expression is frequently downregulated in cancers like lung, breast, and gastric carcinomas, often due to promoter hypermethylation or genomic deletions.

TUSC1 antibodies are immunological tools developed to detect and quantify TUSC1 protein expression in research and diagnostic settings. These antibodies enable studies exploring TUSC1's role in tumorigenesis, its interaction partners, and its clinical relevance as a prognostic biomarker. For example, reduced TUSC1 levels detected via Western blot or immunohistochemistry (IHC) correlate with advanced tumor stages and poor patient outcomes. Additionally, TUSC1 antibodies aid in investigating therapeutic strategies aimed at reactivating its tumor-suppressive functions, such as demethylation therapies or gene delivery systems.

Validated for specificity in applications like ELISA, immunofluorescence, and flow cytometry, TUSC1 antibodies are critical for elucidating molecular mechanisms underlying cancer progression and developing targeted treatments. Ongoing research continues to explore their potential in both basic science and translational oncology contexts.